Playing catch-up to Big Pharma, Moderna posts come-from-behind RSV data

The top-line readout from COVID-19 vaccine maker Moderna for a respiratory syncytial virus (RSV) vaccine seems to keep pace with leading competitors GSK and Pfizer as the three gear up for what is expected to be a very tight commercial market.